Biography

Prof. K. P. Mohanakumar

Inter University Centre for Biomedical Research & Super Speciality Hospital

Managing Director


Email: iucbr@mgu.ac.in


Qualifications

1985 Ph.D., Saurashtra University, Experimental Biology

1979 M.Sc., Aligarh Muslim University, Experimental Biology

1976 B.Sc., Kerala University, Zoology (Main)


Publications (Selected)

  1. Deepthi, V., Sasikumar, A., Mohanakumar, K. P., & Rajamma, U. (2025). Computationally designed multi-epitope vaccine construct targeting the SARS-CoV-2 spike protein elicits robust immune responses in silico. Scientific Reports, 15(1), 9562.
  2. Mohanakumar, K. P., Rendeiro, C., & Beart, P. M. (2025). Neuro-nutraceuticals: Emerging molecular and functional insights into how natural products improve brain health. Neurochemistry International, 105948.
  3. Nair, K. S., Hedger, N., George, R. L., Chandra, G., Mohanakumar, K. P., Chakrabarti, B., & Rajamma, U. (2025). Autistic traits modulate social attention: Evidence for cultural generalizability from a community sample in India.
  4. Jeyabalan, J. B., Pathak, S., Mariappan, E., Mohanakumar, K. P., & Dhanasekaran, M. (2024). Validating the Nutraceutical and Neuroprotective Pharmacodynamics of Flavones. Neurochemistry International, 105829.
  5. Naskar, A., Durgaprasad, G., Biswas, A., & Mohanakumar, K. P. Melatonin in Combination with Pramipexole Treatment Can Reduce the Progression of Rotenone-Induced Parkinsonism in Rats. Available at SSRN 4389562.
  6. Deepthi, V., Mohanakumar, K. P., & Rajamma, U. (2023). Efficacy of defensins as neutralizing agents against the deadly SARS-CoV-2. Journal of Biomolecular Structure and Dynamics, 41(7), 2911-2925.
  7. Govindarajulu, M., Ramesh, S., Neel, L., Fabbrini, M., Buabeid, M., Fujihashi, A., ... & Dhanasekaran, M. (2021). Nutraceutical based SIRT3 activators as therapeutic targets in Alzheimer's disease. Neurochemistry International, 144, 104958.
  8. Dutta, D., Chandra, G., & Mohanakumar, K. P. (2020). The light at the end of the tunnel gets vivid for spinal muscular atrophy: An Editorial Highlight for “Cerebrospinal fluid proteomic profiling in nusinersen‐treated patients with spinal muscular atrophy” on page 650. Journal of Neurochemistry, 153(5), 545-548.
  9. Chakraborti, B., Verma, D., Guhathakurta, S., Jaiswal, P., Singh, A. S., Sinha, S., ... & Rajamma, U. (2020). Gender-specific effect of 5-HT and 5-HIAA on threshold level of behavioral symptoms and sex-bias in prevalence of autism spectrum disorder. Frontiers in Neuroscience, 13, 1375.
  10. Mohanakumar, K., Singh, R., Sengupta, T., Vinayagam, J., Dutta, D., Ali, N., ... & Jaisankar, P. (2019, July). Herbal molecule corrects nigral neuronal mitochondrial dynamics and bioenergetics to protect against experimental PD. In JOURNAL OF NEUROCHEMISTRY (Vol. 150, pp. 197-197). 111 RIVER ST, HOBOKEN 07030-5774, NJ USA: WILEY.
  11. Remya, V. R., Chandra, G., & Mohanakumar, K. P. (2019). Edible mushrooms as neuro-nutraceuticals: basis of therapeutics. Medicinal Mushrooms: Recent Progress in Research and Development, 71-101.
  12. Singh, A., Verma, P., Raju, A., & Mohanakumar, K. P. (2019). Nimodipine attenuates the parkinsonian neurotoxin, MPTP-induced changes in the calcium binding proteins, calpain and calbindin. Journal of Chemical Neuroanatomy, 95, 89-94.
  13. Raju, T. R., & Mohanakumar, K. P. (2019). Neural functions of the aging brain: Daily living, developmental and geriatric disabilities. Journal of Chemical Neuroanatomy, 95, 1-5.
  14. Dutta, D., Ali, N., Banerjee, E., Singh, R., Naskar, A., Paidi, R. K., & Mohanakumar, K. P. (2018). Low levels of prohibitin in substantia nigra makes dopaminergic neurons vulnerable in Parkinson’s disease. Molecular Neurobiology, 55, 804-821.
  15. Nthenge-Ngumbau, D. N., & Mohanakumar, K. P. (2018). Can cyclic nucleotide phosphodiesterase inhibitors be drugs for Parkinson’s disease?. Molecular Neurobiology, 55, 822-834.
  16. Banerjee, R., Raju, A., Nthenge-Ngumbau, D. N., Singh, R., Jaisankar, P., Mohanakumar, K. P., & Biswas, S. C. (2018). Tetrahydroisoquinoline molecule of Indian ayurveda medicine: Therapeutic potential in Parkinson’s disease. Parkinsonism & Related Disorders, 46, e85.
  17. Chandra, G., Shenoi, R. A., Anand, R., Rajamma, U., & Mohanakumar, K. P. (2019). Reinforcing mitochondrial functions in aging brain: An insight into Parkinson's disease therapeutics. Journal of chemical neuroanatomy, 95, 29-42.
  18. Karmakar, A., Goswami, R., Saha, T., Maitra, S., Roychowdhury, A., Panda, C. K., ... & Mukhopadhyay, K. (2017). Pilot study indicate role of preferentially transmitted monoamine oxidase gene variants in behavioral problems of male ADHD probands. BMC medical genetics, 18, 1-12.
  19. Verma, D., Chakraborti, B., Karmakar, A., Nandi, A., Debarshi, P., Sinha, A., ... & Rajamma, U. (2017). Genetic effect of monoamine oxidase B (MAOB) gene on ASD associated behavior phenotypes. Canadian Journal of Biotechnology, 1(Special), 77.
  20. Raju, A., Jaisankar, P., Borah, A., & Mohanakumar, K. P. (2018). 1-methyl-4-phenylpyridinium-induced death of differentiated SH-SY5Y neurons is potentiated by cholesterol. Annals of Neurosciences, 24(4), 243-251.
  21. Paidi, R. K., Nthenge-Ngumbau, D. N., Raju, A., Biswas, S. C., & Mohanakumar, K. P. (2017, August). Garcinol reduces streptozotocin-induced Alzheimer's like phenotypes and neuropathology in rats. In JOURNAL OF NEUROCHEMISTRY (Vol. 142, pp. 245-245). 111 RIVER ST, HOBOKEN 07030-5774, NJ USA: WILEY.
  22. Verma, P., Singh, A., Nthenge-Ngumbau, D. N., Rajamma, U., Sinha, S., Mukhopadhyay, K., & Mohanakumar, K. P. (2016). Attention deficit-hyperactivity disorder suffers from mitochondrial dysfunction. BBA clinical, 6, 153-158.
  23. Sengupta, T., Vinayagam, J., Singh, R., Jaisankar, P., & Mohanakumar, K. P. (2016). Plant-derived natural products for Parkinson’s disease therapy. In The benefits of natural products for neurodegenerative diseases (pp. 415-496). Cham: Springer International Publishing.
  24. Chakraborti, B., Verma, D., Karmakar, A., Jaiswal, P., Sanyal, A., Paul, D., ... & Rajamma, U. (2016). Genetic variants of MAOB affect serotonin level and specific behavioral attributes to increase autism spectrum disorder (ASD) susceptibility in males. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 71, 123-136.
  25. Singh, A., Verma, P., Balaji, G., Samantaray, S., & Mohanakumar, K. P. (2016). Nimodipine, an L-type calcium channel blocker attenuates mitochondrial dysfunctions to protect against 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-induced Parkinsonism in mice. Neurochemistry international, 99, 221-232.


Profile Details

https://orcid.org/0000-0002-4985-1100

https://scholar.google.com/citations?user=HKE7a3EAAAAJ&hl=en

https://www.researchgate.net/profile/Kochupurackal-Mohanakumar

Free SCIRP Newsletters
Copyright © 2006-2026 Scientific Research Publishing Inc. All Rights Reserved.
Top